BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer | $BNTX HKEX: 9606.HK
$BNTX
NASDAQ
BioNTech SE
Market Snapshot
Delayed market data
Market data displayed by TradingView.
Market data may be delayed.
Chart
BioNTech SE
Range
1 month
Chart loads when visible
Latest
Coverage
You are up to date.